Table 1 Studies included in the systematic review and meta-analysis.
Included in systematic review (N = 69) (n, %) | Included in PP-IFI meta-analysis (N = 20) (n, %) | Included in PPP-IFI meta-analysis (N = 36) (n, %) | |
|---|---|---|---|
Total number of patients | 33 968 | 6 334 | 9 744 |
Total number of episodes | 35 781 | 7 261 | 11 247 |
Total number of IFI episodes | 2917 | 744 | 1 348 |
Study period | |||
Beginning study period (year, IQR1-3, range) | 2008 (2004–2012, 1995–2017) | 2009 (2004–2012, 2000–2017) | 2005 (2002–2011, 1996–2017) |
End study period (year, IQR1-3, range) | 2015.5 (2011–2019, 2000–2022) | 2016 (2013-2018.5, 2006–2020) | 2014 (2010.5–2018, 2000–2020) |
Study type | |||
Cohort | 63 (91) | 20 (100) | 35 (97) |
Prospective | 6 (10) | 3 (15) | 4 (11) |
Retrospective | 57 (90) | 17 (85) | 32 (89) |
Case-control study | 6 (9) | 0 (0) | 1 (3) |
Centers | |||
Single-center | 56 (81) | 16 (80) | 30 (83) |
Multicenter | 13 (19) | 4 (20) | 6 (17) |
Type of definition of IFI | |||
EORTC/MSG 20026 | 4 (6) | 0 (0) | 2 (6) |
EORTC/MSG 20087 | 49 (71) | 17 (85) | 30 (82) |
EORTC/MSG 20208 | 13 (19) | 3 (15) | 4 (12) |
Other definition or not specified | 3 (4) | 0 (0) | 0 (0) |
Continent | |||
North America | 24 (35) | 5 (25) | 10 (28) |
Asiaa | 23 (33) | 8 (40) | 14 (38) |
Europe | 18 (26) | 6 (30) | 10 (28) |
South America | 2 (3) | 1 (5) | 2 (6) |
Oceania | 2 (3) | 0 (0) | 0 (0) |
Population | |||
Adults only | 60 (87) | 18 (90) | 29 (80) |
≥ 90% adults | 9 (13) | 2 (10) | 7 (20) |
Hematological malignancies | 42 (61) | 12 (60) | 21 (58) |
Hematological malignancy, any type | 9 (14) | 1 (5) | 3 (8) |
Lymphoproliferative disorder | 10 (14) | 2 (10) | 4 (11) |
Myeloid malignancy | 18 (26) | 6 (30) | 9 (25) |
Otherb | 5 (7) | 3 (15) | 5 (14) |
HSCT | 27 (39) | 8 (40) | 15 (42) |
HSCT, any type | 5 (7) | 1 (5) | 3 (8) |
Allo-HSCT | 20 (29) | 7 (35) | 11 (31) |
Auto-HSCT | 2 (3) | 0 (0) | 1 (3) |
